Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing and able to complete the micturition diary and questionnaires correctly~* Patient has symptoms of overactive bladder for ≥ 3 months~* Patient must experience frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period~* Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence during the 3-day micturition diary period~Exclusion Criteria:~* Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control~* Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Patient has an indwelling catheter or practices intermittent self-catheterization~* Patient has diabetic neuropathy~* Patient has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs~* Patient receives non-drug treatment including electro-stimulation therapy~* Patient has severe hypertension~* Patient has a known or suspected hypersensitivity to YM178, other beta-adrenoreceptor (ß-AR) agonists, or any of the other inactive ingredients~* Patient has been treated with any investigational drug or device within 30 days~* Patient had an average total daily urine volume \> 3000 mL as recorded in the 3-day micturition diary period~* Patient has serum creatinine of \>150 μmol/L, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x upper limit of normal range (ULN), or Gamma glutamyl transferase (γ-GT) \> 3x ULN~* Patient has a clinically significant abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets orally once a day for 12 weeks
- Mirabegron 50 mg (Type: EXPERIMENTAL): Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
- Mirabegron 100 mg (Type: EXPERIMENTAL): Participants received mirabegron 100 m tablets, orally once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).